We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $3.68B invested in Neurocrine Biosciences in 2017 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $3.27B → $3.68B (+$417M)

3% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 37

0.51% more ownership

Funds ownership: 97.13% → 97.64% (+0.51%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less funds holding

Funds holding: 225 → 218 (-7)

10% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 80

39% less call options, than puts

Call options by funds: $12.3M | Put options by funds: $20.3M

Holders
218
Holders Change
-7
Holders Change %
-3.11%
% of All Funds
5.43%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
38
Increased
72
Reduced
80
Closed
37
Calls
$12.3M
Puts
$20.3M
Net Calls
-$8.01M
Net Calls Change
-$6.53M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$214M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$87.4M
3
JHIU
Janus Henderson Investors US
Colorado
+$85.8M
4
Goldman Sachs
Goldman Sachs
New York
+$42.7M
5
Citadel Advisors
Citadel Advisors
Florida
+$30.7M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$80M
2
O
OrbiMed
New York
-$72.3M
3
Millennium Management
Millennium Management
New York
-$51.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$39.4M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$26.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIMCA
226
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$2.02M -52,245 Closed
HCM
227
Highbridge Capital Management
New York
– -$1.9M -49,146 Closed
DCM
228
Dynamic Capital Management
Jersey
– -$1.78M -45,928 Closed
TI
229
Trexquant Investment
Connecticut
– -$1.55M -40,116 Closed
NIT
230
NumerixS Investment Technologies
British Columbia, Canada
– -$1.05M -27,200 Closed
TC
231
TFS Capital
Pennsylvania
– -$909K -23,493 Closed
AIM
232
Assured Investment Management
New York
– -$852K -22,022 Closed
Wolverine Trading
233
Wolverine Trading
Illinois
– -$673K -17,389 Closed
DILIC
234
Dai-ichi Life Insurance Company
Japan
– -$645K -16,677 Closed
TCM
235
Traynor Capital Management
Pennsylvania
– -$537K -13,404 Closed
DTL
236
Dynamic Technology Lab
Singapore
– -$449K -11,601 Closed
ECM
237
Endurant Capital Management
California
– -$445K -11,500 Closed
HI
238
HBK Investments
Texas
– -$437K -11,300 Closed
JG
239
Jefferies Group
New York
– -$357K -9,216 Closed
Nomura Holdings
240
Nomura Holdings
Japan
– -$350K -9,031 Closed
PM
241
Parametrica Management
Hong Kong
– -$329K -8,505 Closed
PHK
242
Point72 Hong Kong
Hong Kong
– -$281K -7,267 Closed
IRF
243
IBM Retirement Fund
New York
– -$267K -6,892 Closed
TSS
244
Two Sigma Securities
New York
– -$201K -5,185 Closed
Asset Management One
245
Asset Management One
Japan
– -$197K -5,163 Closed
Simplex Trading
246
Simplex Trading
Illinois
– -$155K -3,618 Closed
AIM
247
Acrospire Investment Management
Illinois
– -$46K -1,200 Closed
MS
248
Maven Securities
Jersey
– -$21K -567 Closed
NFG
249
Next Financial Group
Texas
– -$9K -230 Closed
QCG
250
Quadrant Capital Group
Ohio
– -$4K -114 Closed
7 8 9
10
11

NBIX Hedge Fund Activity: Q1 2017 in Review

218 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2017, worth a combined $3.68B — up 13% from $3.27B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new NBIX positions and 37 closed out — a net gain of 1 holder — while 72 added to existing stakes and 80 trimmed.

The largest buyer was BlackRock, adding an estimated $214M. The largest seller was T. Rowe Price Associates, cutting an estimated $80M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2017, down from 225 in Q4 2016.
  • Funds reported $3.68B of Neurocrine Biosciences stock for Q1 2017, up 13% quarter-over-quarter.
  • 38 funds opened new Neurocrine Biosciences positions in Q1 2017 and 37 closed out, a net change of +1 holder.
  • The largest Neurocrine Biosciences buyer in Q1 2017 was BlackRock, an estimated $214M added.
  • The largest Neurocrine Biosciences seller in Q1 2017 was T. Rowe Price Associates, an estimated $80M sold.

Based on aggregated 13F filings for Q1 2017.